샘플 요청 목록

 카트 문의
시장보고서
상품코드
1787190

세계의 mRNA 치료제 시장

mRNA Therapeutics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 282 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 mRNA 치료제 세계 시장, 2030년에는 345억 달러에 이를 전망

2024년에 133억 달러로 추정되는 mRNA 치료제 세계 시장은 2024-2030년의 분석 기간에 CAGR 17.1%로 성장하여 2030년에는 345억 달러에 이를 것으로 예측됩니다. 보고서에서 분석한 부문 중 하나인 예방 제품은 18.3%의 연평균 성장률을 기록하며 분석 기간이 끝날 때까지 256억 달러에 달할 것으로 예상됩니다. 치료 제품 부문의 성장은 분석 기간 동안 14.2%의 CAGR로 추정됩니다.

미국 시장은 36억 달러로 추정, 중국은 CAGR 22.8%로 성장 예측

미국의 mRNA 치료제 시장은 2024년에 36억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 분석 기간인 2024-2030년 CAGR22.8%로 성장하여 2030년까지 77억 달러 규모에 이를 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 12.6%와 15.5%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 약 13.7%를 나타낼 전망입니다.

세계 mRNA 치료제 시장 - 주요 동향 및 촉진요인 정리

mRNA 치료제는 의약품 개발 및 질병 치료에 어떤 혁명을 가져올 것인가?

mRNA 치료제의 등장은 의약품 개발의 상황을 근본적으로 바꾸고 있으며, 감염성 질환과 암에서 유전성 질환과 희귀질환에 이르기까지 다양한 질병을 치료할 수 있는 강력한 플랫폼을 제공합니다. 복잡한 제조 공정과 세포배양 시스템을 필요로 하는 기존 생물학적 제제와 달리, mRNA 기반 치료제는 합성 메신저 RNA를 활용하여 치료용 단백질을 체내에서 직접 생산하도록 세포에 지시합니다. 이러한 접근 방식은 의약품 개발 기간을 크게 단축하고 질병 경로를 표적으로 삼을 때 정확도를 높일 수 있습니다. 코로나19 mRNA 백신의 획기적인 성공은 이 기술의 속도와 유연성을 입증하고, mRNA의 응용을 백신 외의 분야로 확대하려는 연구가 급증하고 있습니다. 거의 모든 단백질을 mRNA 서열로 코딩할 수 있기 때문에 이 기술은 개인의 유전자 프로파일에 맞는 치료가 가능한 개인 맞춤형 의료의 유망한 도구로 자리매김하고 있습니다. 또한, 지질 나노입자(LNP) 전달 시스템의 발전으로 mRNA 치료제의 안정성과 표적 전달이 개선되어 분해 및 면역원성과 관련된 이전의 문제를 해결하고 있습니다. 제약회사와 연구기관이 mRNA 기반 솔루션에 대한 투자를 지속하면서 자가면역질환, 심혈관계 질환, 신경퇴행성 질환 등의 치료 가능성은 빠르게 확대되고 있으며, mRNA 치료제는 현대 생명공학에서 가장 역동적인 분야 중 하나가 되었습니다.

어떤 기술 발전이 mRNA 약물의 효능과 전달을 향상시키는가?

mRNA 치료제의 급속한 발전은 제형화, 전달 기술, 서열 최적화의 발전에 크게 좌우되고 있습니다. 가장 중요한 돌파구 중 하나는 mRNA의 안정성을 높이고 불필요한 면역반응을 억제하는 N1-메틸슈도우리딘과 같은 화학적 변형 뉴클레오타이드의 개발입니다. 체외 전사(IVT) 공정의 개선으로 mRNA의 수율과 순도가 향상되었고, 염증 반응을 유발하는 이중 가닥 RNA의 혼입이 감소했습니다. 지질 나노입자(LNP) 캐리어의 개선 또한 mRNA 전달을 개선하는 데 중요한 역할을 하며, 치료 페이로드가 표적 조직에 고효율로 도달하는 동시에 표적 외 영향을 최소화하는 데 중요한 역할을 합니다. 연구팀은 현재 조직 특이성과 치료 효과의 지속성을 더욱 높이기 위해 고분자 기반 나노입자, 엑소좀 유래 소포, 펩타이드 기반 제제 등 차세대 전달 시스템을 모색하고 있습니다. 또한, 자가증폭형 mRNA(saRNA)의 출현으로 mRNA 농도를 낮춰 치료용 단백질을 생산할 수 있게 되어, 더 적은 용량으로 더 오래 지속되는 치료의 새로운 가능성을 열었습니다. 인공지능(AI)과 머신러닝이 신약개발에 접목되면서 예측 모델링이 mRNA 서열과 전달 전략의 최적화에 활용되고, mRNA를 이용한 새로운 치료제 개발이 가속화되고 있습니다. 이러한 기술적 진보는 mRNA 치료제의 범위를 확장하고 여러 질병 영역에 걸쳐 새로운 치료 패러다임을 열어줄 것으로 기대되고 있습니다.

규제 및 제조 이슈가 mRNA 치료제 시장에 어떤 영향을 미치고 있는가?

mRNA 치료제의 큰 잠재력에도 불구하고 업계는 규제 및 제조 문제에 직면해 있습니다. mRNA 생산은 고도로 전문화되어 있기 때문에 특히 원료 조달, 시험관 내 전사, 정제 과정에서 엄격한 품질 관리 대책이 요구됩니다. FDA 및 EMA와 같은 규제 기관은 제품의 안정성, 면역원성, 제조 확장성에 중점을 둔 mRNA 치료제에 대한 새로운 가이드라인을 도입하고 있습니다. 제조관리 및 품질관리기준(GMP)을 준수하는 제조시설의 필요성으로 인해 mRNA 의약품 제조를 전문으로 하는 개발제조수탁기관(CDMO)에 대한 수요가 증가하고 있습니다. 그러나 뉴클레오타이드, 캡핑 시약, 지질 운반체 등 주요 성분의 세계 공급망은 여전히 단절되기 쉬워 대규모 생산의 위험요소로 작용하고 있습니다. 또한, 개별 환자 맞춤형 제제를 필요로 하는 암 백신과 같은 개인 맞춤형 mRNA 치료제의 경우, 규제 프레임워크가 아직 개발 중입니다. 또한, mRNA 기반 의약품은 전 세계 유통을 위해 콜드체인 보관과 고도의 물류가 필요한 경우가 많기 때문에 제조 비용도 중요한 과제입니다. 이러한 과제를 해결하기 위해서는 생명공학 기업, 규제 당국, 제조 파트너가 지속적으로 협력하여 mRNA 치료제가 전 세계적으로 효율적이고 안전하게 개발 및 유통될 수 있도록 해야 합니다.

mRNA 치료제 시장을 촉진하는 주요 성장 요인은?

mRNA 치료제 시장의 성장은 생명공학 연구에 대한 투자 증가, 백신 이외의 응용 분야 확대, mRNA 전달 시스템의 기술 발전 등 여러 요인에 의해 이루어지고 있습니다. mRNA 기반 코로나19 백신의 성공으로 mRNA 연구에 대한 자금이 크게 증가하면서 암, 대사성 질환, 독감, HIV, 지카 바이러스 등 감염성 질환에 대한 mRNA 치료법을 연구하는 임상시험에 대한 자금이 유입되고 있습니다. 또한, 개인 맞춤형 의료의 부상으로 환자가 특정 종양 항원을 표적으로 하는 맞춤형 치료를 받는 mRNA 기반 암 백신에 대한 관심이 가속화되고 있습니다. 또한, AI를 활용한 신약개발이 확대되면서 mRNA 서열 설계가 간소화되고, 제형이 최적화되어 개발 기간이 단축되고 있습니다. 분산형 백신 생산과 지역 제조 허브에 대한 수요 증가는 mRNA 생산 시설에 대한 투자를 촉진하여 시장 확대를 더욱 촉진하고 있습니다. 지질 나노입자 및 대체 전달 시스템의 지속적인 개선으로 mRNA 의약품의 효능과 안전성이 향상되어 보다 광범위한 임상 적용을 촉진하고 있습니다. 또한, 전염병 대비와 바이오 의약품 혁신에 초점을 맞춘 정부의 이니셔티브는 mRNA 치료제에 대한 자금 및 규제 지원을 제공합니다. 새로운 적응증이 등장하고 생산 능력이 향상됨에 따라 mRNA 치료제 시장은 지속적으로 성장하여 많은 질병의 치료 전망에 혁명을 일으켜 mRNA 기술을 차세대 의료의 초석으로 자리 매김하고 있습니다.

부문

제품 유형(예방 제품, 치료 제품), 용도(감염증 용도, 암 용도, 희소 유전자 질환 용도, 호흡기 질환 용도, 기타 용도), 최종 용도(병원 및 클리닉 최종 용도, 연구기관 최종 용도, 기타 최종 용도)

조사 대상 기업 예

  • Abogen Biosciences
  • Alnylam Pharmaceuticals
  • Anima Biotech
  • Arcturus Therapeutics Holdings Inc.
  • BioNTech SE
  • Comanche Biopharma
  • CureVac N.V.
  • eTheRNA Immunotherapies NV
  • Ethris GmbH
  • EXACIS Biotherapeutics
  • Gritstone bio, Inc.
  • HC Bioscience
  • Inflammatix, Inc.
  • Ionis Pharmaceuticals
  • Moderna, Inc.
  • Nutcracker Therapeutics
  • Orna Therapeutics
  • ReCode Therapeutics
  • Strand Therapeutics
  • Translate Bio(acquired by Sanofi)

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 일반적인 LLM나 업계별 SLM 쿼리에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.08.18

Global mRNA Therapeutics Market to Reach US$34.5 Billion by 2030

The global market for mRNA Therapeutics estimated at US$13.3 Billion in the year 2024, is expected to reach US$34.5 Billion by 2030, growing at a CAGR of 17.1% over the analysis period 2024-2030. Prophylactic Products, one of the segments analyzed in the report, is expected to record a 18.3% CAGR and reach US$25.6 Billion by the end of the analysis period. Growth in the Therapeutic Products segment is estimated at 14.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.6 Billion While China is Forecast to Grow at 22.8% CAGR

The mRNA Therapeutics market in the U.S. is estimated at US$3.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$7.7 Billion by the year 2030 trailing a CAGR of 22.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.6% and 15.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.7% CAGR.

Global mRNA Therapeutics Market - Key Trends & Drivers Summarized

How Are mRNA Therapeutics Revolutionizing Drug Development and Disease Treatment?

The rise of mRNA therapeutics has fundamentally changed the landscape of drug development, offering a powerful platform for treating a wide range of diseases, from infectious diseases and cancer to genetic disorders and rare conditions. Unlike traditional biologics, which require complex production processes and cell culture systems, mRNA-based therapies leverage synthetic messenger RNA to instruct cells to produce therapeutic proteins directly within the body. This approach significantly accelerates drug development timelines and enhances precision in targeting disease pathways. The groundbreaking success of mRNA COVID-19 vaccines demonstrated the speed and flexibility of this technology, leading to a surge in research efforts aimed at expanding mRNA applications beyond vaccines. The ability to encode virtually any protein into an mRNA sequence has positioned this technology as a promising tool for personalized medicine, where treatments can be tailored to an individual’s genetic profile. Additionally, advancements in lipid nanoparticle (LNP) delivery systems have improved the stability and targeted delivery of mRNA therapeutics, addressing previous challenges related to degradation and immunogenicity. As pharmaceutical companies and research institutions continue to invest in mRNA-based solutions, the potential for treating conditions such as autoimmune diseases, cardiovascular disorders, and neurodegenerative conditions is rapidly expanding, making mRNA therapeutics one of the most dynamic areas in modern biotechnology.

What Technological Advancements Are Enhancing the Efficacy and Delivery of mRNA Drugs?

The rapid evolution of mRNA therapeutics is largely driven by advancements in formulation, delivery technologies, and sequence optimization. One of the most significant breakthroughs has been the development of chemically modified nucleotides, such as N1-methylpseudouridine, which enhance mRNA stability and reduce unwanted immune responses. Improved in vitro transcription (IVT) processes have increased mRNA yield and purity, reducing the presence of double-stranded RNA contaminants that can trigger inflammatory responses. The refinement of lipid nanoparticle (LNP) carriers has also played a crucial role in improving mRNA delivery, ensuring that the therapeutic payload reaches target tissues with high efficiency while minimizing off-target effects. Researchers are now exploring next-generation delivery systems, including polymer-based nanoparticles, exosome-derived vesicles, and peptide-based formulations, to further enhance tissue specificity and prolonged therapeutic effects. Additionally, the emergence of self-amplifying mRNA (saRNA) has opened new possibilities for lower-dose, longer-lasting treatments by enabling the production of therapeutic proteins at reduced mRNA concentrations. As artificial intelligence (AI) and machine learning are integrated into drug discovery, predictive modeling is being used to optimize mRNA sequences and delivery strategies, accelerating the development of novel mRNA-based therapies. These technological advancements are expected to expand the scope of mRNA therapeutics, unlocking new treatment paradigms across multiple disease areas.

How Are Regulatory and Manufacturing Challenges Impacting the mRNA Therapeutics Market?

Despite the immense potential of mRNA therapeutics, the industry faces regulatory and manufacturing challenges that must be addressed to enable widespread adoption. The highly specialized nature of mRNA production requires stringent quality control measures, particularly in raw material sourcing, in vitro transcription, and purification processes. Regulatory agencies such as the FDA and EMA have introduced new guidelines for mRNA therapeutics, focusing on product stability, immunogenicity, and manufacturing scalability. The need for Good Manufacturing Practice (GMP)-compliant production facilities has increased demand for contract development and manufacturing organizations (CDMOs) that specialize in mRNA drug production. However, the global supply chain for key components such as nucleotides, capping reagents, and lipid carriers remains vulnerable to disruptions, posing risks to large-scale manufacturing. Additionally, regulatory frameworks are still evolving for personalized mRNA therapies, such as cancer vaccines, which require customized formulations for individual patients. Another key challenge is the cost of production, as mRNA-based drugs often require cold-chain storage and sophisticated logistics for global distribution. Addressing these challenges will require continued collaboration between biotech companies, regulatory agencies, and manufacturing partners to ensure that mRNA therapeutics can be developed and distributed efficiently and safely on a global scale.

What Are the Key Growth Drivers Propelling the mRNA Therapeutics Market?

The growth in the mRNA therapeutics market is driven by several factors, including increasing investments in biotechnology research, expanding applications beyond vaccines, and technological advancements in mRNA delivery systems. The success of mRNA-based COVID-19 vaccines has significantly boosted funding for mRNA research, leading to an influx of clinical trials investigating mRNA therapies for cancer, metabolic diseases, and infectious diseases such as influenza, HIV, and Zika virus. The rise of personalized medicine has also accelerated interest in mRNA-based cancer vaccines, where patients receive customized treatments targeting specific tumor antigens. Additionally, the growing adoption of AI-driven drug discovery is streamlining mRNA sequence design, optimizing formulations, and reducing development timelines. The increasing demand for decentralized vaccine production and regional manufacturing hubs has spurred investments in mRNA production facilities, further supporting market expansion. The continued refinement of lipid nanoparticles and alternative delivery systems has enhanced the efficacy and safety of mRNA drugs, driving broader clinical adoption. Furthermore, government initiatives focused on pandemic preparedness and biopharmaceutical innovation are providing funding and regulatory support for mRNA therapeutics. As new indications emerge and manufacturing capabilities improve, the mRNA therapeutics market is poised for sustained growth, revolutionizing the treatment landscape for numerous diseases and positioning mRNA technology as a cornerstone of next-generation medicine.

SCOPE OF STUDY:

The report analyzes the mRNA Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Prophylactic Products, Therapeutic Products); Application (Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application, Other Applications); End-Use (Hospitals & Clinics End-Use, Research Organizations End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • Abogen Biosciences
  • Alnylam Pharmaceuticals
  • Anima Biotech
  • Arcturus Therapeutics Holdings Inc.
  • BioNTech SE
  • Comanche Biopharma
  • CureVac N.V.
  • eTheRNA Immunotherapies NV
  • Ethris GmbH
  • EXACIS Biotherapeutics
  • Gritstone bio, Inc.
  • HC Bioscience
  • Inflammatix, Inc.
  • Ionis Pharmaceuticals
  • Moderna, Inc.
  • Nutcracker Therapeutics
  • Orna Therapeutics
  • ReCode Therapeutics
  • Strand Therapeutics
  • Translate Bio (acquired by Sanofi)

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • mRNA Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Investment in mRNA Technology for Therapeutic Development Drives Market Growth
    • Surge in Global Demand for mRNA-Based Vaccines Expands Market Opportunity for mRNA Therapeutics
    • Accelerated Research and Development in mRNA-Based Cancer Therapies Expands Market Horizons
    • Regulatory Support and Fast-Track Approvals for mRNA Therapies Strengthen Market Confidence and Adoption
    • Technological Advancements in mRNA Delivery Systems Propel Growth in Therapeutic Applications
    • Rising Consumer Demand for Personalized Medicine Drives Adoption of mRNA Therapeutics in Tailored Treatment Plans
    • The Emergence of mRNA-based Infectious Disease Treatments Spells Long-term Growth for the Therapeutics Market
    • Increasing Use of mRNA Vaccines in Global Immunization Campaigns Accelerates Market Adoption
    • The Shift Toward Preventive Healthcare and Proactive Disease Management Boosts Demand for mRNA Therapeutics
    • Growing Integration of mRNA Technology into Cancer Immunotherapies Expands Market Opportunity
    • Increasing Collaborations Between Biopharma Companies and Research Institutions Fuel mRNA Therapeutics Innovation
    • The Global COVID-19 Pandemic Drives Significant Investment and Infrastructure Development for mRNA Therapeutics
    • Expansion of Clinical Trials for mRNA Therapeutics in Rare and Genetic Diseases Spurs Market Potential
    • Rising Focus on the Safety and Efficacy of mRNA-based Therapies Strengthens Consumer Confidence and Adoption
    • The Growing Role of Artificial Intelligence and Machine Learning in mRNA Therapeutics Development Drives Innovation
    • Expansion of Manufacturing Capabilities for mRNA-based Drugs Increases Market Accessibility and Scalability
    • Increasing Global Health Initiatives and Public-Private Partnerships Accelerates Demand for mRNA Therapeutics
    • The Rise of mRNA-based Protein Replacement Therapies Strengthens Market Demand for mRNA in Genetic Disorders
    • Regulatory and Ethical Issues Surrounding mRNA Technology Drive Innovation in Safety Protocols and Guidelines
    • Increasing Interest in mRNA as a Platform for Targeted Therapies Expands Addressable Market Opportunity for Therapeutic Products
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World mRNA Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for mRNA Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for mRNA Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Prophylactic Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Prophylactic Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Therapeutic Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Therapeutic Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Research Organizations End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Infectious Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Infectious Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Rare Genetic Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Rare Genetic Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Respiratory Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Respiratory Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 24: USA Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • CANADA
    • TABLE 30: Canada Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • JAPAN
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 36: Japan Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 40: Japan Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • CHINA
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 42: China Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 46: China Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • EUROPE
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 48: Europe Recent Past, Current & Future Analysis for mRNA Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for mRNA Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • FRANCE
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 58: France Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • GERMANY
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 64: Germany Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 66: Germany Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 70: Italy Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 72: Italy Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • UNITED KINGDOM
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 76: UK Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 78: UK Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 82: Spain Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Spain 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 84: Spain Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Spain 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 88: Russia Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Russia 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 90: Russia Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Russia 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 94: Rest of Europe Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of Europe 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 96: Rest of Europe Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of Europe 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • ASIA-PACIFIC
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for mRNA Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific 6-Year Perspective for mRNA Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2025 & 2030
    • TABLE 100: Asia-Pacific Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Asia-Pacific 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 102: Asia-Pacific Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Asia-Pacific 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • AUSTRALIA
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 106: Australia Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Australia 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 108: Australia Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Australia 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • INDIA
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 112: India Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 113: India 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 114: India Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 115: India 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • SOUTH KOREA
    • TABLE 118: South Korea Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 119: South Korea 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 120: South Korea Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 121: South Korea 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 124: Rest of Asia-Pacific Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Rest of Asia-Pacific 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 126: Rest of Asia-Pacific Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • LATIN AMERICA
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 130: Latin America Recent Past, Current & Future Analysis for mRNA Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 131: Latin America 6-Year Perspective for mRNA Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2025 & 2030
    • TABLE 132: Latin America Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 133: Latin America 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 136: Latin America Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 137: Latin America 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • ARGENTINA
    • TABLE 138: Argentina Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 139: Argentina 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 142: Argentina Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 143: Argentina 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • BRAZIL
    • TABLE 144: Brazil Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 145: Brazil 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 148: Brazil Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 149: Brazil 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • MEXICO
    • TABLE 150: Mexico Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 151: Mexico 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 154: Mexico Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 155: Mexico 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 156: Rest of Latin America Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 157: Rest of Latin America 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 160: Rest of Latin America Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 161: Rest of Latin America 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • MIDDLE EAST
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 162: Middle East Recent Past, Current & Future Analysis for mRNA Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 163: Middle East 6-Year Perspective for mRNA Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 166: Middle East Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 167: Middle East 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 168: Middle East Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 169: Middle East 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 172: Iran Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 173: Iran 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 174: Iran Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 175: Iran 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 178: Israel Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 179: Israel 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 180: Israel Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 181: Israel 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 184: Saudi Arabia Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 185: Saudi Arabia 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 186: Saudi Arabia Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 187: Saudi Arabia 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 190: UAE Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 191: UAE 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 192: UAE Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 193: UAE 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 196: Rest of Middle East Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 197: Rest of Middle East 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 198: Rest of Middle East Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 199: Rest of Middle East 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030
  • AFRICA
    • mRNA Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for mRNA Therapeutics by Type - Prophylactic Products and Therapeutic Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa 6-Year Perspective for mRNA Therapeutics by Type - Percentage Breakdown of Value Sales for Prophylactic Products and Therapeutic Products for the Years 2025 & 2030
    • TABLE 202: Africa Recent Past, Current & Future Analysis for mRNA Therapeutics by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 203: Africa 6-Year Perspective for mRNA Therapeutics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Research Organizations End-Use for the Years 2025 & 2030
    • TABLE 204: Africa Recent Past, Current & Future Analysis for mRNA Therapeutics by Application - Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 205: Africa 6-Year Perspective for mRNA Therapeutics by Application - Percentage Breakdown of Value Sales for Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application and Other Applications for the Years 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제